Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: Preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)

Cancer Cell International

Volumn 9, Issue , 2009, Pages

  Tsui, Sam Mui ^a   Lam, Wai Man ^b   Lam, Tin Lun ^a   Chong, Hiu Chi ^a   So, Pui Kin ^b   Kwok, Sui Yi ^b   Arnold, Simon ^a   Cheng, Paul ^a   Wheatley, Denys N ^a,c   Lo, Wai Hung ^b   Leung, Yun Chung ^b  

^a Bio Cancer Treatment International Limited   (Hong Kong)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c BioMedES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MACROGOL DERIVATIVE; METHOXYPOLYETHYLENE GLYCOL CYANURIC CHLORIDE; METHOXYPOLYETHYLENE GLYCOL MALEIMIDE; METHOXYPOLYETHYLENE GLYCOL N HYDROXYSUCCINIMIDE; METHOXYPOLYETHYLENE GLYCOL PROPIONALDEHYDE; METHOXYPOLYETHYLENE GLYCOL SUCCINIMIDYL PROPIONATE; RECOMBINANT HUMAN ARGINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CATALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME ACTIVITY; ESCHERICHIA COLI; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE;

EID: 65649127785     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-9-9     Document Type: Article

References (31)

1. Wheatley DN Controlling cancer by restricting arginine availability - arginine-catabolizing enzymes as anticancer agents Anticancer Drugs 2004, 5:825-833. 10.1097/00001813-200410000-00002
2. Wheatley DN Campbell E Lai PBS Cheng PNM A rational approach to the systemic treatment of cancer involving medium-term depletion of arginine Gene Ther Mol Biol 2005, 9:33-40.
3. Cheng PN Leung YC Lo WH Tsui SM Lam KC Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: Arginase as a potential drug candidate for hepatocellular carcinoma Cancer Lett 2005, 224:67-80. 15911102
4. Cheng PN Lam TL Lam WM Tsui SM Cheng AW Lo WH Leung YC Pegylated recombinant human arginase (rhArg1-peg5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion Cancer Res 2007, 67:309-317. 10.1158/ 0008-5472.CAN-06-1945 17210712
5. Cheng P Wheatley DN Arginine deprivation addresses the Achilles Heel of Cancer: Urea cycle deficiencies in melanoma, HCC and other cancers Oncology News 2008, 2(4):6-8.
6. Takaku H Takase M Abe S Hayashi H Miyazaki K In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini Int J Cancer 1992, 51:244-249. 10.1002/ijc.2910510213 1568792
7. Ensor CM Holtsberg FW Bomalaski JS Clark MA Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo Cancer Res 2002, 62:5443-5450. 12359751
8. Broome JD Studies on the mechanism of tumor inhibition by L-asparaginase. Effects of the enzyme on asparagine levels in the blood, normal tissues, and 6C3HEB lymphomas of mice: Differences in asparagine formation and utilisation in asparaginase-sensitive and -resistant lymphoma cells J Exp Med 1968, 127:1055-1072. 2138499 4871211 10.1084/ jem.127.6.1055
9. Sun X Yang Z Li S Tan Y Zhang N Wang X Yagi S Yoshioka T Takimoto A Mitsushima K Suginaka A Frenkel EP Hoffman RM In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5′-phosphate supplementation Cancer Res 2003, 63:8377-8383. 14678999
10. Ash DE Structure and function of arginases J Nutr 2004, 134:2760S-2764S. 15465781
11. Cheng NM Leung YC Lo WH US Patent no. 20050244398 2005.
12. Ikemoto M Tabata M Miyake T Kono T Mori M Totani M Murachi T Expression of human liver arginase in Escherichia coli. Purification and properties of the product Biochem J 1990, 270:697-703. 1131788 2241902
13. Roberts MJ Harris JM Attachment of degradable poly(ethylene glycol) to proteins has the potential to increase therapeutic efficacy J Pharm Sci 1998, 87:1440-1445. 10.1021/js9800634 9811503
14. Harris JM Martin NE Modi M Pegylation: A novel process for modifying pharmacokinetics Clin Pharmacokinet 2001, 40:539-551. 10.2165/ 00003088-200140070-00005 11510630
15. Harris JM Chess RB Effect of pegylation on pharmaceuticals Nat Rev Drug Discov 2003, 2:214-221. 10.1038/nrd1033 12612647
16. Roberts MJ Bentley MD Harris JM Chemistry for peptide and protein PEGylation Adv Drug Deliv Rev 2002, 54:459-476. 10.1016/ S0169-409X(02)00022-4 12052709
17. Goodson RJ Katre NV Site-directed pegylation of recombinant interleukin-2 at its glycosylation site Biotechnology (N Y) 1990, 8:343-346. 10.1038/nbt0490-343 1366535
18. Baker DE Pegylated interferons Rev Gastroenterol Disord 2001, 1:87-99. 12120178
19. Savoca KV Davis FF van Es T McCoy JR Palczuk NC Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia Cancer Biochem Biophys 1984, 7:261-268 6488153
20. Ikemoto M Tabata M Murachi T Totani M Purification and properties of human erythrocyte arginase Ann Clin Biochem 1989, 26:547-553 2515788
21. Holtsberg FW Ensor CM Steiner MR Bomalaski JS Clark MA Poly(ethylene glycol) (PEG) conjugated arginine deiminase: Effects of PEG formulations on its pharmacological properties J Control Release 2002, 80:259-271 10.1016/S0168-3659(02)00042-1 11943403
22. Ascierto PA Scala S Castello G Daponte A Simeone E Ottaiano A Beneduce G De Rosa V Izzo F Melucci MT Ensor CM Prestayko AW Holtsberg FW Bomalaski JS Clark MA Savaraj N Feun LG Logan TF Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies J Clin Oncol 2005, 23:7660-7668 10.1200/JCO.2005.02.0933 16234528
23. Goffin V Touraine P Pegvisomant Pfizer/Sensus Curr Opin Investig Drugs 2004, 5:463-468 15134290
24. Carvajal N Salas M Lopez V Uribe E Herrera P Cerpa J Fuentes M Manganese-dependent inhibition of human liver arginase by borate J Inorg Biochem 1999, 77:163-167 10.1016/S0162-0134(99)00187-7 10643656
25. Savoca KV Abuchowski A van Es T Davis FF Palczuk NC Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol Biochim Biophys Acta 1979, 578:47-53 454671
26. Bowen S Tare N Inoue T Yamasaki M Okabe M Horii I Eliason JF Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein Exp Hematol 1999, 27:425-432 10.1016/S0301-472X(98)00051-4 10089904
27. Kamada H Tsutsumi Y Yamamoto Y Kihira T Kaneda Y Mu Y Kodaira H Tsunoda SI Nakagawa S Mayumi T Antitumor activity of tumor necrosis factor-alpha conjugated with polyvinylpyrrolidone on solid tumors in mice Cancer Res 2000, 60:6416-6420 11103807
28. Gong H Zolzer F von Recklinghausen G Havers W Schweigerer L Arginine deiminase inhibits proliferation of human leukemia cells more potently than asparaginase by inducing cell cycle arrest and apoptosis Leukemia 2000, 14:826-9 10.1038/sj.leu.2401763 10803513
29. Philip R Campbell E Wheatley DN Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures Br J Cancer. 2003, Feb 24;88(4):613-23
30. Izzo F Marra P Beneduce G Castello G Vallone P De Rosa V Cremona F Ensor CM Holtsberg FW Bomalaski JS Clark MA Ng C Curley SA Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies J Clin Oncol 2004, 22:1815-1822 10.1200/JCO.2004.11.120 15143074
31. Sreerama N Venyaminov SY Woody RW Estimation of protein secondary structure from circular dichroism spectra: Inclusion of denatured proteins with native proteins in the analysis Anal Biochem 2000, 287:243-251 10.1006/abio.2000.4879 11112270